Long non-coding RNA LETN serving as tumor marker and therapeutic target point
AssigneeTsinghua University
InventorsXuerui Yang, Xianteng Wang, Xiaolin Hu
Life of this patent
Estimating the term…
Abstract
The invention relates to a long non-coding RNA (LETN) useful as a diagnostic and therapeutic target for cancer. In particular, the invention discloses that lncRNA RP11-196G18.22 (LETN) is overexpressed in cancer cells, and such overexpression can promote the proliferation of cancer cells and are associated with short prognostic survival time in cancer patients. Reducing the expression of this lncRNA results in the inhibition of cancer cell growth, and thus inhibiting the expression of this lncRNA represents a new strategy for cancer therapy.
Claims4
A method for treating cancer, the method comprising administrating to a subject in need thereof an effective amount of an agent for reducing or inhibiting the expression of lncRNA RP11-196G18.22 (LETN),
- wherein the cancer is a solid tumor selected from the group consisting of liver hepatocellular carcinoma, lung cancer, and prostate cancer.
Dependencies are inferred from the claim text.